S A2 COLUMN 0D 2.0-3.5 2.0-3.5 % ACETAMINOPHEN 0D 5-25 5-25 > 150 ug/ml > 50 ug/ml 12 hour post ingestion > 100 ug/ml 8 hour post ingestion > 200 ug/ml 4 hour post ingestion ACTIVATED PROTEIN C RESIS 0D 2-10 2-10 RATIO ALBUMIN 0D 3.3-5.0 3.3-5.0 g/dl ALBUMIN - FLUID 0D CSF: 40-70% of Total Protein g/dl PERITONEAL FL:.32-1.64 g/dl PLEURAL FL:.80-1.22 g/dl ALT (SGPT) 0D 0.0-41 0.0-31 u/l ALKALINE PHOSPHATASE 0D 40-350 40-350 u/l 10 40-280 40-280 15 40-150 40-150 20 30-120 30-120 AMIKACIN - RANDOM 0D > 10 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 8 ug/ml TRADITIONAL DOSING 25-30 ug/ml < 8 ug/ml TOXIC VALUES > 35 ug/ml > 10 ug/ml AMIKACIN - PEAK 0D 25-30 25-30 > 35 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 8 ug/ml TRADITIONAL DOSING 25-30 ug/ml < 8 ug/ml TOXIC VALUES > 35 ug/ml > 10 ug/ml AMIKACIN - THROUGH 0D 0-8 0-8 > 10 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 8 ug/ml TRADITIONAL DOSING 25-30 ug/ml < 8 ug/ml TOXIC VALUES > 35 ug/ml > 10 ug/ml 1 Reviewed: 1/04/13
S AMMONIA 0D 11-35 11-35 > 150 umol/l 11 11-35 11-35 AMNISURE 0D NEGATIVE NEGATIVE AmniSure is an immunochromatographic assay for PAMG-1, an amniotic fluid protein. Detection of PAMG-1 in vaginal fluid is evidence of ruptured fetal membranes. Results should be interpreted in conjunction with clinical and other laboratory findings AMYLASE 0D 25-125 25-125 u/l AMYLASE - FLUID 0D 34-122 34-122 u/l ANTICARDIOLIPIN PROFILE ANTICARDIOLIPIN IgG 0D 0-23 0-23 GPL ANTICARDIOLIPIN IgM 0D 0-11 0-11 MPL ANTI NUCLEAR ANTIBODY 0D NEGATIVE NEGATIVE ANTITHROMBIN 3 ACTIVITY 0D 85-135 85-135 % APTT 0D 27.0-37.0 27.0-37.0 > 120 SEC ASLO 0D <200 <200 IU/mL AST (SGOT) 0D 0.0-37 0.0-31 u/l BARBITURATES - SERUM 0D NEGATIVE NEGATIVE BENZODIAZEPINES - SERUM 0D NEGATIVE NEGATIVE BILIRUBIN - DIRECT 0D 0.0-0.2 0.0-0.2 mg/dl BILIRUBIN - FLUID 0D 0-1.4 0-1.4 mg/dl BILIRUBIN - TOTAL 0D 2.0-6.0 2.0-6.0 > 15 mg/dl 1D 6.0-10.0 6.0-10.0 > 15 3D 4.0-8.0 4.0-8.0 > 15 6D 0.2-1.2 0.2-1.2 > 15 29D 0.2-1.2 0.2-1.2 BLEEDING TIME 0D 3.0-9.0 3.0-9.0 MINS 2 Reviewed: 1/04/13
S BNP 0D BNP results less than or equal to 100 pg/ml are representative pg/ml of patients without CHF. BNP results greater than 100 pg/ml are considered abnormal and suggestive of patients with CHF. High BNP concentrations measured in the first 72 hours after an acute coronary syndrome are associated with an increased risk of death, myocardial infarction and CHF. BUN 0D 7-23 7-23 mg/dl BUN - POST DIALYSIS 0D 9-20 7-17 mg/dl BUN - PRE DIALYSIS 0D 9-20 7-17 mg/dl BUN - FLUID 0D CSF: 15-40 mg/dl SALIVA: 0-14 STIMULATED SALIVA (CHILDREN): 20-36 PLEURAL FLUID: 10-25 BUN - URINE 24 HOUR 0D 12000-20000 12000-20000 mg/24 HR C3 0D 90-180 90-180 mg/dl C4 0D 10-40 10-40 mg/dl C. DIFFICILE TOXIN by PCR 0D NOT DETECTED NOT DETECTED C. DIFFICILE TOXIN CYTOTOXICITY 0D NEGATIVE NEGATIVE C PEPTIDE 0D 0.80-3.90 0.80-3.90 ng/ml C REACTIVE PROTEIN 0D 0-5.0 0-5.0 mg/l CAFFEINE 0D 10-25 10-25 > 80 ug/ml CALCIUM 0D 8.4-10.5 8.4-10.5 < 6.5 > 13.0 mg/dl CALCIUM - FLUID 0D 8.5-10.5 8.5-10.5 mg/dl CALCIUM - URINE 24 HOUR 0D 5-300 5-300 mg/24hr The 24 hour excretion of calcium is highly diet dependent. General guidelines are as follows: Calcium free diet: 5-40 mg/day Low to average: 50-150 mg/day Average (800 mg/day): 100-300 mg/day 3 Reviewed: 1/04/13
S CALCIUM - IONIZED 0D 1.03-1.23 1.03-1.23 < 0.7 mmol/l CARBAMAZEPINE 0D 4-12 4-12 > 14 ug/ml CEA - CARCINOEMBRYOGENIC ANTIGEN 0D 0.0-3.8 0.0-3.8 ng/ml CHLAMYDIA DNA PROBE 0D NEGATIVE NEGATIVE CHLORIDE 0D 96-108 96-108 mmol/l CHLORIDE - CSF 0D 111-130 111-130 meq/l 3 118-132 118-132 CHLORIDE - FLUID 0D 90-110 90-110 meq/l GASTRIC JUICE: 8-100 BILE: 83-110 PANCREATIC JUICE: 54-95 SMALL BOWEL: 69-127 ILEOSTOMY: 43-122 CHLORIDE - SWEAT 0D mmol/l INTERPRETATION OF RESULTS: Sweat Chloride for infants < 6 months old: Negative <= 29 mmol/l Borderline / Indeterminate 30-59 mmol/l Positive >= 60 mmol/l Consistent with a diagnosis of Cystic Fibrosis Sweat Chloride for patients >= 6 months old: Negative <= 39 mmol/l Borderline / Indeterminate 40-59 mmol/l Positive >= 60 mmol/l Consistent with a diagnosis of Cystic Fibrosis Sweat weight was sufficient for testing. SUGGEST REPEAT ING AS CLINICALLY INDICATED CHLORIDE - URINE 24 HOUR 0D 2-10 2-10 mmol/24 2 15-176 15-176 15 110-250 110-250 CHOLESTEROL 0D 120-199 120-199 mg/dl CK TOTAL 0D 30-200 25-170 u/l CKMB 0D < 6.7 < 4.8 ng/ml 4 Reviewed: 1/04/13
S CKMB RELATIVE INDEX 0D 0-2.5 0-2.5 CMV IgG 0D NEGATIVE NEGATIVE CMV IgM 0D NEGATIVE NEGATIVE CO2 0D 22-31 22-31 <10 >45 mmol/l CORTISOL 0D 2.3-19.4 2.3-19.4 ug/dl AM COLLECTION 6.2-19.4 ug/dl PM COLLECTION 2.3-11.9 ug/dl CPK TOTAL 0D 30-230 30-230 u/l CREATININE 0D 0.2-0.7 0.2-0.7 mg/dl 10 0.5-1.3 0.5-1.3 CREATININE - FLUID 0D 0-1.40 0-1.40 mg/dl CREATININE - URINE 24 HOUR 0D 800-1800 600-1600 mg/24hr CRP 0D 0-5.0 0-5.0 mg/l CRP - SENSITIVITY 0D <3.0 <3.0 mg/l D-DIMER 0D 0-230 0-230 ng/ml DDU A result less than <230 ng /ml DDU correlates with the absence of thrombosis in a patient with low and moderate pre-test probability of thrombosis. DIGOXIN 0D 0.8-2.0 0.8-2.0 >2.5 ng/ml DRUG SCREEN - SERUM Expected values: 0.8-2.0 ng/ml 4-6 hours post administration ACETAMINOPHEN 0D 5-25 5-25 > 150 ug/ml ACETAMINOPHEN VALUES ARE RELATED TO TIME OF INGESTION. TOXIC VALUES > 50 ug/ml 12 hour post ingestion > 100 ug/ml 8 hour post ingestion > 200 ug/ml 4 hour post ingestion 5 Reviewed: 1/04/13
S BARBITURATES 0D NEGATIVE NEGATIVE BENZODIAZEPINES 0D NEGATIVE NEGATIVE ETHANOL 0D <10 <10 mg/dl SALICYLATE 0D 15-30 15-30 >40 mg/dl TOXIC VALUES ACUTE INGESTION > 80 mg/dl CHRONIC INGESTION > 40 mg/dl TRICYCLIC ANTIDEPRESSANTS 0D NEGATIVE NEGATIVE CUT OFF VALUE BARBITURATES < 0.5 ug/ml TRICYCLIC ANTIDEPRESSANTS < 300 ng/ml BENZODIAZEPINES < 200 ng/ml DRUG SCREEN - URINE SERUM DRUG SCREENS ARE PERFORMED USING THE CUT OFF LEVELS LISTED ABOVE. THESE RESULTS SHOULD BE USED FOR MEDICAL PURPOSES ONLY ARE NOT FOR EMPLOYEE SCREENING OR LEGAL PURPOSES. WE SUGGEST CLINICAL CORRELATION AND CONFIRMATORY DRUG ING IF INDICATED. AMPHETAMINE CLASS 0D NEGATIVE NEGATIVE BARBITURATES 0D NEGATIVE NEGATIVE BENZODIAZEPINES 0D NEGATIVE NEGATIVE CANNABINOIDS 0D NEGATIVE NEGATIVE COCAINE / METABOLITE 0D NEGATIVE NEGATIVE METHADONE 0D NEGATIVE NEGATIVE OPIATES 0D NEGATIVE NEGATIVE OXYCODONE 0D NEGATIVE NEGATIVE PHENCYCLIDINE 0D NEGATIVE NEGATIVE 6 Reviewed: 1/04/13
S CUT OFF VALUE AMPHETAMINE CLASS < 1000 ng/ml BARBITURATES < 200 ng/ml BENZODIAZEPINES < 300 ng/ml CANNABINOIDS < 50 ng/ml COCAINE/METABOLITE < 300 ng/ml METHADONE < 300 ng/ml OPIATES < 300 ng/ml PHENCYCLIDINE < 25 ng/ml OXYCODONE < 100 ng/ml URINE DRUG SCREENS ARE PERFORMED USING THE CUT OFF LEVELS LISTED ABOVE. CROSS REACTIVITY WITH OTHER MEDICATIONS MAY OCCUR. WE SUGGEST CLINICAL CORRELATION AND CONFIRMATORY DRUG ING IF INDICATED. THESE RESULTS ARE FOR MEDICAL PURPOSES ONLY AND SHOULD NOT BE USED FOR EMPLOYEE SCREENING OR LEGAL PURPOSES. A COMPREHENSIVE OF CROSS-REACTING DRUGS IS AVAILABLE IN THE LABORATORY. DRVVT 0D 37-50 37-50 SEC ETHANOL - SERUM 0D < 10 < 10 mg/dl ETHANOL - URINE 0D < 10 < 10 mg/dl FACTOR 2 0D 50-150 50-150 % FACTOR 5 0D 50-150 50-150 % FACTOR 5 LEIDEN 0D NO MUTATION NO MUTATION FACTOR 7 0D 50-150 50-150 % FACTOR 8 0D 50-200 50-200 % FACTOR 9 0D 50-150 50-150 % FACTOR 10 0D 50-150 50-150 % FACTOR 11 0D 50-200 50-200 % FACTOR 12 0D 50-200 50-200 % FERRITIN 0D 30-400 15-150 ng/ml 7 Reviewed: 1/04/13
S FETAL FIBRONECTIN 0D NEGATIVE NEGATIVE FETAL HGB ALKALINE DENATURE 0D 50-90 50.0-90.0 % 1M 50-80 50-80 2M 20-50 20-50 3M 2-30 2-30 6M 2-8 2-8 1 0.5-2.0 0.5-2.0 FIBRINOGEN 0D 225-500 225-500 < 100 mg/dl FLUID IMMUNOQUANTITATION FLUID IMMUNO IgA 0D 0 0 mg/dl FLUID IMMUNO IgG 0D 0 0 mg/dl FLUID IMMUNO IgM 0D 0 0 mg/dl FLUID KAPPA 0D 0 0 mg/dl FLUID LAMBDA 0D 0 0 mg/dl FOLATE 0D 3.1-17.5 3.1-17.5 ng/ml GC DNA PROBE 0D NEGATIVE NEGATIVE GENTAMICIN - PEAK 0D 4-10 4-10 > 10.0 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml GENTAMICIN - RANDOM 0D >2.0 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml GENTAMICIN - THROUGH 0D 0.4-2 0.4-2 > 2.0 ug/ml 8 Reviewed: 1/04/13
S PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml GGT 0D 8-61 5-36 u/l GLUCOSE 0D 70-99 70-99 < 45 > 450 mg/dl GLUCOSE - CHALLENGE 0D 65-115 65-115 mg/dl POST DOSE 51 85-125 85-125 GLUCOSE - CSF 0D 60-80 60-80 mg/dl 14 40-70 40-70 GLUCOSE - FLUID 0D 60-110 60-110 mg/dl GLUCOSE - 2 HOUR PP 0D 65-115 65-115 mg/dl 51 85-125 85-125 GLUCOSE TOLERANCE FASTING 0D 70-108 70-108 < 45 > 450 mg/dl 60 70-125 70-125 < 45 > 450 1/2 HOUR 0D 110-170 110-170 < 40 > 350 mg/dl 1 HOUR 0D 120-170 120-170 < 40 > 350 mg/dl 1 1/2 HOUR 0D 110-170 110-170 < 40 > 350 mg/dl 2 HOUR 0D 70-120 70-120 < 40 > 350 mg/dl 3 HOUR 0D 70-115 70-115 < 40 > 350 mg/dl 51 80-125 80-125 < 40 > 350 4 HOUR 0D 70-115 70-115 < 40 > 350 mg/dl 51 80-125 80-125 < 40 > 350 5 HOUR 0D 70-115 70-115 < 40 > 350 mg/dl 51 80-125 80-125 < 40 > 350 GLUCOSE - URINE 24 HOUR 0D 0-500 0-500 mg/24hr 9 Reviewed: 1/04/13
S HAPTOGLOBIN 0D 34-200 34-200 mg/dl HCG 0D < 5.0 < 5.0 miu/ml GROUP HCG-QUANT miu/ml Male: Less than 5 Non-pregnant females: Less than 5 Indeterminant females: 5-25 Weeks of pregnancy: miu/ml 3 6-71 4 10-750 5 220-7,100 6 160-32,000 7 3,700-164,000 8 32,000-150,000 9 64,000-151,000 10 47,000-187,000 12 28,000-211,000 14 14,000-63,000 15 12,000-71,000 16-18 8,000-58,000 HcTi DABIGATRAN 0D 0 0 ug/ml Peak (2 hours post dose): 0.06-0.44 ug/ml Through (12 hours post dose): 0.03-0.23 ug/ml *****************ATTENTION********************* This test was developed and it's performance characteristics determined by Medical Laboratory at Long Island Jewish Medical Center. It has not been cleared or approved by the US Drug and Food Administration. The results of this test should be used in conjunction with clinical findings and coagulation tests including APTT. HDL CHOLESTEROL 0D 35-55 45-65 mg/dl 10 Reviewed: 1/04/13
S HEMOGLOBIN A1C 0D 4.0-5.6 4.0-5.6 % High risk (pre-diabetic) 5.7-6.4 % Diabetic - diagnostic > 6.5 % ADA diabetic treatment goal < 7.0 % HbA1C values may not accurately reflect mean blood glucose in patients with Hb variants. Suggest clinical correlation. HEMOGLOBIN A 0D 10-50 10-50 % 1D 50-90 50-90 1M 70-98 70-98 6M 90-98 90-98 2 96-99 96-99 HEMOGLOBIN C 0D 0 0 % HEMOGLOBIN F 0D 50-90 50-90 % 1M 2-50 2-50 6M 2-8 2-8 1 0.5-2 0.5-2 HEMOGLOBIN S 0D 0 0 % HEPARIN INDUCED THROMBOCYTOPENIA 0D 0.00-0.39 0.00-0.39 HEPARIN SCREEN HEPARIN SCREEN APTT 0D 23.4-36.0 23.4-36.0 SEC HEPARIN SCREEN PT 0D 9.8-13.3 9.8-13.3 SEC HEPATITIS A ANTIBODY 0D NEGATIVE NEGATIVE HEPATITIS B CORE IgM ANTIBODY 0D NEGATIVE NEGATIVE HEPATITIS B SURFACE ANTIGEN 0D NEGATIVE NEGATIVE HEPATITIS B SURFACE ANTIBODY 0D NEGATIVE NEGATIVE HEPATITIS B SURFACE ANTIBODY - Quant. 0D miu/ml NEGATIVE = < 5.0 miu/ml INDETERMINATE = 5.0-12.0 miu/ml POSITIVE = > 12.0 miu/ml 11 Reviewed: 1/04/13
S HEPATITIS C ANTIBODY 0D NEGATIVE NEGATIVE MOLECULAR WT. KININOGEN 0D 50-150 50-150 % PHOSPOLIPID DRVVT 0D 0-1.2 0-1.2 RATIO HIV - 1/2 ANTIBODY SCREEN by EIA 0D NON-REACTIVE NON-REACTIVE IMMUNOGLOBULIN - SERUM IGA QUANTITATIVE 0D 0-83 0-83 mg/dl 1 20-100 20-100 4 27-195 27-195 7 34-305 34-305 10 53-204 53-204 12 58-358 58-358 14 47-249 47-249 16 61-348 61-348 20 70-400 70-400 IGE QUANTITATIVE 0D 0-2.0 0-2.0 IU/mL 1M 0-15 0-15 2 0-60 0-60 6 0-90 0-90 10 0-200 0-200 16 0-100 0-100 IGG QUANTITATIVE 0D 232-1411 232-1411 mg/dl 1 453-916 453-916 4 504-1464 504-1464 7 572-1474 572-1474 10 698-1560 698-1560 12 759-1549 759-1549 14 716-1711 716-1711 16 549-1584 549-1584 20 700-1600 700-1600 IGM QUANTITATIVE 0D 0-145 0-145 mg/dl 1 19-146 19-146 4 24-210 24-210 7 31-208 31-208 10 31-179 31-179 12 35-239 35-239 14 15-188 15-188 16 23-259 23-259 12 Reviewed: 1/04/13
S 20 40-230 40-230 INFLUENZA A ANTIGEN 0D NEGATIVE NEGATIVE INFLUENZA B ANTIGEN 0D NEGATIVE NEGATIVE INHIBITOR ASSAY 0D 0 0 BU INR 0D 0.86-1.18 0.86-1.18 > 4.0 IRON 0D 45-165 30-160 ug/dl IRON BINDING CAPACITY - 0D 110-370 110-370 ug/dl UNSATURATED (UIBC) LACTATE 0D 0.5-2.2 0.5-2.2 > 4.0 mmol/l LACTATE - CSF 0D 1.1-6.7 1.1-6.7 mmol/l 3D 1.1-4.4 1.1-4.4 11D 1.1-2.8 1.1-2.8 18 1.1-2.4 1.1-2.4 LD 0D 135-225 135-225 U/L LDL - DIRECT 0D 10-160 10-160 mg/dl LEUK ALK PHOSPHATASE 0D 20-137 20-137 LIPASE 0D 7-60 7-60 U/L LITHIUM 0D 0.6-1.2 0.6-1.2 >1.5 mmol/l LYME DISEASE SCREEN 0D NEGATIVE NEGATIVE MAGNESIUM 0D 1.6-2.6 1.6-2.6 < 1.0 >7.0 mg/dl MAGNESIUM - URINE 24 HOUR 0D 50-160 50-160 mg/24 Hr MALARIA SCREEN 0D NEGATIVE NEGATIVE MEASLES IgG 0D NEGATIVE NEGATIVE METHOTREXATE 0D umol/l <= 5.0 umol/l at 24 hours <= 1.0 umol/l at 48 hours <= 0.1 umol/l at 72 hours 13 Reviewed: 1/04/13
S MIXING STUDY PT INHIBITOR SCREEN - 0 HR 0D 9.6-15.3 9.6-15.3 SEC PT INHIBITOR SCREEN - 2 HR 0D 9.6-15.3 9.6-15.3 SEC PT NORMAL POOL PLASMA 0D 9.8-15.3 9.8-15.3 SEC PTT INHIBITOR SCREEN - 0 HR 0D 27.0-37.0 27.0-37.0 SEC PTT INHIBITOR SCREEN - 2 HR 0D 27.0-37.0 27.0-37.0 SEC PTT NORMAL POOL PLASMA 0D 27.0-37.0 27.0-37.0 SEC MONONUCLEOSIS 0D NEGATIVE NEGATIVE MUMPS VIRUS IgG 0D NEGATIVE NEGATIVE OCCULT BLOOD 0D NEGATIVE NEGATIVE OSMOLALITY 0D 275-295 275-295 mosmo/kg OSMOLALITY - 24 HOUR URINE 0D 300-900 300-900 mosmo/kg OSMOLALITY - RANDOM URINE 0D 50-1200 50-1200 mosmo/kg P2Y12 PLATELET REACTIVITY 0D 194-418 194-418 PRU Assay performance may be affected by Hematocrit values < 33% or > 53% or a Platelet count < 119 or > 502 k/ul PHENOBARBITAL 0D 10-40 10-40 > 50 ug/ml PHENYTOIN (DILANTIN) 0D 10-20 10-20 > 30 ug/ml PHOSPHORUS - INORGANIC 0D 4.2-9.0 4.2-9.0 < 1.0 mg/dl 6W 3.8-6.7 3.8-6.7 < 1.0 18M 2.9-5.9 2.9-5.9 < 1.0 3 3.6-5.6 3.6-5.6 < 1.0 16 2.5-4.5 2.5-4.5 < 1.0 PHOSPHORUS - INORGANIC - URINE 24 H 0D 900-1300 900-1300 mg/dl PLASMA VISCOSITY 0D 1.7-2.2 1.7-2.2 14 Reviewed: 1/04/13
S PLASMINOGEN ACTIVITY 0D 70-140 70-140 % POTASSIUM 0D 3.5-5.1 3.5-5.1 < 3.0 > 6.2 mmol/l POTASSIUM - CSF 0D 2.5-3.2 2.5-3.2 meq/l CSF Potassium is generally 70% of plasma value POTASSIUM - FLUID 0D 2.5-6.6 2.5-6.6 meq/l CSF 2.2-2.9 RBC 108-114 LYMPH 3.9-5.6 PERITONEAL 2.0-5.6 PLEURAL FLUID 2.5-6.6 PROSTATIC FLUID 29-61 SALIVA 14-38 SYNOVIAL FLUID 3.5-4.5 TRANSUDATES 2.8-6.0 POTASSIUM - URINE 24 HOUR 0D 25-125 25-125 mmol/24h PRE-ALBUMIN 0D 20-40 20-40 mg/dl pro-bnp 0D < 300 < 300 pg/ml ACUTE CONGESTIVE HEART FAILURE is UNLIKELY if NT-proBNP is < 300 pg/ml. CONSIDER ACUTE CONGESTIVE HEART FAILURE if: NT-proBNP RESULT < 50 YEARS > 450 pg/ml 50-75 YEARS > 900 pg/ml > 75 YEARS > 1800 pg/ml All results require clinical correlation. Consider obtaining a baseline or "dry" NT-proBNP level when the patient is stabilized, so that subsequent levels can be compared to that value. Patients with recurrent CHF may have elevated NT-proBNP levels. Acute failure episodes generally produce levels at least 25% greater than baseline levels. The above values are derived from a large multi-center international study, "Januzzi, JL, et al, European Heart Journal, 2006; 27:330-337." PROTEIN - TOTAL 0D 6.0-8.3 6.0-8.3 g/dl 15 Reviewed: 1/04/13
S PROTEIN - CSF 0D 15-130 15-130 mg/dl 29D 15-45 15-45 PROTEIN - URINE RANDOM 0D <12 <12 mg/dl PROTEIN - URINE 24 HOUR 0D <150 <150 mg/24 Hr PROTEIN C ACTIVITY 0D 74-150 74-150 % PROTEIN C ANTIGEN 0D 59-155 59-155 % PROTEIN S ACTIVITY 0D 70-140 70-140 % PROTEIN S ANTIGEN, FREE 0D 67-141 60-131 % PROTIME 0D 9.6-13.3 9.6-13.3 SEC PTH INTACT 0D 12-65 12-65 pg/ml RETIC PROFILE RETIC % 0D 2.5-6.5 2.5-6.5 % 8D 0.1-1.7 0.1-1.7 2M 0.5-1.5 0.5-1.5 18 0.5-2.5 0.5-2.5 ABSOLUTE RETIC # 0D.017-0.073.017-0.073 10x6/uL RETIC % - MANUAL 0D 0.5-2.5 0.5-2.5 % RHEUMATOID FACTOR 0D <14.0 <14.0 IU/mL ROTAVIRUS 0D NEGATIVE NEGATIVE RPR 0D NonReactive NonReactive RSV ANTIGEN 0D NEGATIVE NEGATIVE RUBELLA IgG 0D < 10.0 < 10.0 IU/mL NEGATIVE < 9.9 POSITIVE 10.0-14.9 POSITIVE > 15.0 16 Reviewed: 1/04/13
S SALICYLATES 0D 15-30 15-30 >40 mg/dl TOXIC VALUES ACUTE INGESTION > 80 mg/dl CHRONIC INGESTION > 40 mg/dl SEDIMENTATION RATE 0D 0-20 0-20 mm/hr 18 1-15 4-25 SICKLE CELL SCREEN 0D NEGATIVE NEGATIVE SODIUM 0D 132-145 132-145 <125 >155 mmol/l 29D 132-145 132-145 <120 >160 SODIUM - CSF 0D 138-150 138-150 meq/l SODIUM -FLUID 0D 110-160 110-160 meq/l SODIUM - URINE 24 HOUR 0D 40-220 40-220 mmol/24h SPINAL IMMUNOQUANTITATION SPINAL IgA 0D 0.1-0.3 0.1-0.3 mg/dl SPINAL IgG 0D 1-2 1-2 mg/dl SPINAL IgM 0D 0-0.1 0-0.1 mg/dl T3 TOTAL 0D 0.8-2.0 0.8-2.0 ng/ml T UPTAKE 0D 0.8-1.3 0.8-1.3 TBI T4 0D 5.1-13.0 5.1-13.0 ug/dl THEOPHYLLINE 0D 5-20 5-20 >20 ug/ml THROMBIN TIME 0D 19.0-27.0 19.0-27.0 SEC TOBRAMYCIN - PEAK 0D 6-10 6-10 > 10 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml 17 Reviewed: 1/04/13
S TOBRAMYCIN - RANDOM 0D ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml TOBRAMYCIN - THROUGH 0D 0.3-2.0 0.3-2.0 > 2.0 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml TOXOPLASMA IgG 0D NEGATIVE NEGATIVE TOXOPLASMA IgM 0D NEGATIVE NEGATIVE TRICYCLIC ANTIDEPRESSANTS 0D NEGATIVE NEGATIVE TROPONIN-T 0D < = 0.06 < = 0.06 ng/ml TRIGLYCERIDES 0D 10-149 10-149 mg/dl TSH 0D 0.27-4.20 0.27-4.20 uiu/ml URIC ACID 0D 3.4-8.8 2.5-7.0 mg/dl URIC ACID (24 HR. URINE) 0D 250-800 250-800 mg/24 hrs. VANCOMYCIN - RANDOM 0D >25 ug/ml Reference Range Trough 10-20 ug/ml Toxic > 25 ug/ml Random values require clinical correlation VANCOMYCIN - TROUGH 0D 10-20 10-20 >25 ug/ml Vancomycin trough levels should be rapidly reached and maintained at 15-20 ug/ml for life threatening MRSA infections such as sepsis, endocarditis, osteomyelitis and pneumonia. A first trough level should be drawn before the 3rd or 4th dose. Risk of renal toxicity is increased for levels >15 ug/ml, in patients on other nephrotoxic drugs, who are hemodynamically unstable, have unstable renal function, or are on vancomycin therapy for >14 days. Renal function with creatinine levels should be monitored for those patients. 18 Reviewed: 1/04/13
S VARICELLA ZOSTER ANTIBODY 0D NEGATIVE NEGATIVE VISCOSITY PLASMA 0D 1.7-2.2 1.7-2.2 VISCOSITY SERUM 0D 1.4-1.8 1.4-1.8 VISCOSITY WHOLE BLOOD 0D 3.5-5.4 3.5-5.4 VITAMIN B12 0D 200-900 200-900 pg/ml VWF ACTIVITY 0D 43-126 43-126 % THIS IS AN ENHANCED LATEX IMMUNO-TURBIDIMETRIC ASSAY. THE ESTABLISHED BY NSLIJHS LABORATORY IS FOR PATIENTS OF ALL BLOOD TYPES. THERE IS VARIABILITY DUE TO BLOOD TYPE (ER VALUES FOR TYPE O). THE RESULT IS ALSO AFFECTED BY ACUTE PHASE REACTION AND SHOULD BE INTERPRETED IN THE CONTEXT OF THE CLINICAL SETTING FOR THE PATIENT. THE PRESENCE OF RHEUMATOID FACTOR >200 IU/ML MAY CAUSE FALSE ELEVATION OF VWF ACTIVITY. VWF ANTIGEN 0D 50-150 50-150 % 19 Reviewed: 1/04/13